[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Huons Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":109},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,63,87],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100641239","phase-2-dose-finding-study-of-huc1-394-in-participants-with-dry-eye-disease-100641239",false,"NCT07656688","Dose-Finding Study of HUC1-394 in Participants With Dry Eye Disease","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Clinical Study to Evaluate the Efficacy and Safety of HUC1-394 in Participant With Dry Eye Disease","Inclusion Criteria:\n\n* Adults aged ≥ 19 years at the time of screening\n* Trial participants who have experienced at least one of the following dry eye disease symptoms for at least 3 months prior to the time of screening\n* Trial participants who meet all of the following criteria in at least one eye (left or right) at the time of screening and randomization:\n\nTCSS (NEI grading) ≥ 4 \u002F Non-anesthetic Schirmer test result \\> 0 mm and ≤ 10 mm\u002F5 min \u002F TBUT \\\u003C 7 seconds\n\n* OSDI score ≥ 23 at the time of screening\n* Trial participants who have provided voluntary written informed consent after receiving a full explanation and understanding of the clinical trial\n\nExclusion Criteria:\n\n* Trial participants with clinically significant ophthalmic diseases that may confound the interpretation of clinical trial results\n* Trial participants with blepharospasm, entropion, ectropion, or abnormalities of the eyelashes\n* Trial participants with any active ophthalmic disease that may affect the ocular surface, such as active allergy, anterior uveitis, and Stevens-Johnson syndrome\n* Trial participants with a history of corneal transplantation or neurotrophic keratitis\n* Trial participants with autoimmune diseases or immunodeficiency disorders\n* Pregnant or lactating women, or women of childbearing potential and men of reproductive potential who plan to conceive during the clinical trial or are unwilling to use an appropriate method of contraception\n* Trial participants who have participated in another clinical trial and received an investigational product or used an investigational medical device within 30 days prior to the time of screening\n* Trial participants who are deemed ineligible for participation by the investigator for any other reason in the clinical trial","ALL","19 Years",{"count":19,"type":20},150,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Clinical trial aims to determine the optimal dosing regimen by evaluating the efficacy and safety of HUC1-394 across different dosing frequencies in patients with moderate to severe dry eye disease.",[26],"Dry Eye Disease (DED)","RECRUITING","2026-06-29",{"date":30,"type":31},"2026-07-01","ACTUAL",{"date":33,"type":20},"2026-07",{"date":35,"type":20},"2027-07",{"name":37,"class":38},"Huons Co., Ltd.","INDUSTRY",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":39},"100618714","phase-3-efficacy-and-safety-of-huc3-637-in-patients-with-primary-open-angle-glaucoma-or-ocular-hypertension-100618714","NCT07335211","Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension","A Multicenter, Randomized, Single-blind, Active Controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension","Inclusion Criteria:\n\n* Adults aged 19 years and older\n* Participants diagnosed with POAG or OH\n* Have fully explained and understood the study and have voluntarily given written informed consent.\n\nExclusion Criteria:\n\n* Acute or chronic angle-closure glaucoma\n* Congenital glaucoma, secondary glaucoma (open-angle glaucoma)",{"count":48,"type":20},206,[50],"PHASE3","A multicenter, randomized, single-blind, active controlled, phase III clinical trial to evaluate the efficacy and safety of HUC3-637 in patients with primary open angle glaucoma or ocular hypertension",[53,54],"Primary Open Angle Glaucoma (POAG)","Ocular Hypertension","2026-01-11",{"date":57,"type":31},"2026-01-13",{"date":59,"type":20},"2026-01",{"date":61,"type":20},"2027-12",{"name":37,"class":38},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":70,"sex":16,"minAge":17,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":21,"phases":74,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":4},"100618865","phase-1-study-to-compare-and-evaluate-the-safety-and-pharmacokinetics-after-subcutaneous-injection-of-huc2-676-or-huc2-676-r-in-healthy-adult-subjects-100618865","NCT07337174","Study to Compare and Evaluate the Safety and Pharmacokinetics After Subcutaneous Injection of HUC2-676 or HUC2-676-R in Healthy Adult Subjects","A Randomized, Open-label, Single Dose, Two-way, Crossover, Phase 1 Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics After Subcutaneous Injection of HUC2-676 or HUC2-676-R in Healthy Adult Subjects","Inclusion Criteria:\n\n* Healthy adult volunteers aged 19 to 65 years, inclusive, at screening.\n* Subjects who have been fully informed of the details of this clinical trial, have fully understood the information, have voluntarily decided to participate, and have provided written informed consent to comply with all protocol requirements throughout the trial period.\n\nExclusion Criteria:\n\n* Subjects with a current or past clinically significant medical history of hepatic, renal, neurological, psychiatric, respiratory, endocrine, hematologic, oncologic, genitourinary, cardiovascular, gastrointestinal, musculoskeletal, or other disorders.\n* For females: Pregnant women (positive urine hCG) or nursing mothers.",true,"65 Years",{"count":73,"type":20},40,[75],"PHASE1","The trial uses a randomized, open-label, single-dose administration per period, and a 2 x 2 crossover design where subjects receive both treatments sequentially with a washout.",[78],"Obesity","NOT_YET_RECRUITING","2026-01-06",{"date":57,"type":31},{"date":83,"type":20},"2026-01-25",{"date":85,"type":20},"2026-03-24",{"name":37,"class":38},{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":70,"sex":16,"minAge":17,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":21,"phases":97,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":39},"100536374","phase-1-clinical-study-for-the-evaluation-of-safety-and-tolerability-of-ncp112-eye-drops-100536374","NCT06263998","Clinical Study for the Evaluation of Safety and Tolerability of NCP112 Eye Drops","A Randomized, Double-blind, Parallel, Placebo-Controlled, Single and Multiple Ascending Dose Phase 1 Clinical Study to Assess the Safety, and Local Tolerance, Pharmacokinetics After Application of NCP112 Eye Drop in Healthy Subjects","Inclusion Criteria:\n\n1. Healthy adult subjects aged 19 to 50 years at the time of screening (Visit 1).\n2. Subjects with a body weight of 50.0 kg or more, and a body mass index (BMI) between 18.0 kg\u002Fm² and 30.0 kg\u002Fm² at the time of screening (Visit 1).\n\n   ※ Body Mass Index (BMI, kg\u002Fm²) = Weight (kg) \u002F \\[Height (m)\\]²\n3. Subjects who have received sufficient explanation about the clinical trial, fully understand it, and have voluntarily decided to participate and signed the written informed consent.\n4. Subjects deemed suitable as participants for this clinical trial based on the investigators judgment after physical examination, clinical laboratory tests, and medical history obtained during screening (Visit 1).\n\nExclusion Criteria:\n\n1. Subjects with clinically significant diseases or history of diseases related to the liver, kidneys, cardiovascular system, gastrointestinal system, respiratory system, musculoskeletal system, endocrine system, neuropsychiatric system (such as epilepsy, mood disorders, obsessive-compulsive disorder), hematologic\u002Foncologic system, or urinary system (chronic or recurrent urinary tract infections).\n2. Subjects with hepatitis B or C.\n3. Subjects meeting any of the following criteria based on ophthalmologic history or examination during screening (Visit 1):\n\n   * Corrected visual acuity of 20\u002F40 or less.\n   * Intraocular pressure exceeding 21 mmHg in either eye.\n   * History of lacrimal drainage system disease or abnormal tear drainage.\n   * History or suspicion of conditions affecting visual organs such as keratitis, iritis, uveitis, retinitis, dry eye syndrome, strabismus, glaucoma, etc.\n   * Experience of adverse effects from contact lens use, or contact lens use within one month prior to the anticipated first dose, or inability to abstain from contact lens use during the clinical trial.\n   * Ophthalmologic surgery (intraocular surgery) or laser vision correction surgery (such as LASIK) within 12 months prior to the anticipated first dose.\n   * Silicone punctal occlusion or punctal cauterization within 3 months prior to the anticipated first dose (collagen punctal occlusion within 1 month).\n   * Any other abnormal findings from ophthalmologic examination.\n4. Subjects with a history of hypersensitivity to the active ingredients or excipients of the investigational drug, or to drugs in the same class as the active ingredients.\n5. Subjects who have taken any medications related to dry eye syndrome (e.g., artificial tears, anti-inflammatory agents like cyclosporine, hyaluronic acid preparations, tetracycline preparations) or drugs that could induce dry eye syndrome or affect the outcome of this clinical trial (e.g., oral contraceptives, antihistamines, sedatives, oral aspirin, corticosteroids) within one month prior to the anticipated first dose.\n6. Subjects who have taken any prescription drugs, eye drops other than those for dry eye, oriental medicine, or any other health supplements, including liver function supplements or vitamins within 2 weeks of the expected first dosing date, or any over-the-counter drugs within 1 week (unless other conditions are deemed appropriate by the investigator).\n7. Subjects who have taken drug metabolism inducers or inhibitors, such as barbiturates, within one month prior to the expected first dosing date\n8. Subjects with a history of drug abuse or a positive result on a urine drug test at screening (Visit 1).\n9. Subjects unable to restrict grapefruit or grapefruit-containing food consumption from 7 days prior to the anticipated first dose through the duration of the clinical trial.\n10. Subjects with systolic blood pressure of 90 mmHg or less, or 140 mmHg or more, or diastolic blood pressure of 50 mmHg or less, or 90 mmHg or more after sitting for at least 3 minutes without sudden postural changes during screening (Visit 1).\n11. Subjects with a history of alcohol abuse, or who have consumed alcohol regularly (more than 21 units\u002Fweek, 1 unit = 10 g = 12.5 mL of pure alcohol) within one month prior to the anticipated first dose, or are unable to abstain from alcohol during the clinical trial.\n12. Subjects who regularly consume caffeine (e.g., coffee or green tea more than 5 units\u002Fday) or are unable to abstain from caffeine-containing foods from 24 hours prior to hospitalization through the duration of the clinical trial.\n13. Subjects who have regularly smoked (including e-cigarettes, more than 10 cigarettes\u002Fday) within one month prior to the anticipated first dose, or are unable to abstain from smoking during the clinical trial.\n14. Subjects who test positive on a breath alcohol test at screening (Visit 1).\n15. Subjects who have participated in another clinical trial and received an investigational drug within 6 months prior to the anticipated first dose.\n16. Subjects who have donated whole blood within 2 months, or component blood within 1 month, or received a blood transfusion within 1 month prior to the anticipated first dose, or who plan to donate or receive blood during the clinical trial.\n17. Subjects who have received a vaccine within 14 days prior to the anticipated first dose or are expected to receive a vaccine during the trial period.\n18. Female participants who test positive on a pregnancy test (urine hCG) conducted before the start of investigational drug administration, are pregnant, or are breastfeeding, except for those who have undergone surgical sterilization (Bilateral tubal ligation, Bilateral oophorectomy, or Hysterectomy).\n19. Subjects who, during the entire clinical trial period and for at least 90 days after the last dose of the investigational drug, cannot or do not agree to use medically acceptable double contraception methods, or whose partner cannot or does not agree to use medically acceptable contraception, or who do not agree to refrain from donating sperm during this period.\n\n    ※ Medically acceptable contraception methods include:\n    * Use of an intrauterine device (IUD) with a documented failure rate by the partner.\n    * Double contraception (use of barrier methods by both male and female partners).\n    * Surgical sterilization of the subject or partner (vasectomy, tubal ligation, hysterectomy).\n20. Subjects deemed unsuitable for participation by the investigator for other reasons (e.g., non-compliance with instructions).","50 Years",{"count":96,"type":20},60,[75],"The objective is to evaluate the safety, local tolerability, and pharmacokinetics of NCP112 eye drops through single and multiple dose-escalation ocular administrations in healthy adults.",[100],"Xerophthalmia","2024-09-27",{"date":103,"type":31},"2024-10-01",{"date":105,"type":31},"2024-07-11",{"date":107,"type":20},"2026-01-30",{"name":37,"class":38},""]